Kyverna Therapeutics is set to seek FDA approval for a one-time cell therapy designed to treat stiff person syndrome, a rare neurological condition.
The therapy has demonstrated significant improvements in patient mobility during late-stage trials, indicating its potential effectiveness.
The company plans to submit the necessary documentation for approval later this year, marking a crucial step in the development of this treatment.